CSL Ltd Share Price and Fundamentals (CSL)

Overview

CSL Ltd is one of the ASX’s best-known healthcare names, with a global footprint across plasma therapies, influenza products and iron deficiency and nephrology treatments. For Australian investors, it stands out for its scale, international diversification and long operating history, but the current share price story is more complicated than the business pedigree alone. CSL is trading at A$168.30, leaving the stock well above its 50-day and 200-day moving averages, yet still below its 52-week high of A$219.64. That mix suggests a share that has recovered meaningfully from earlier weakness, even as the latest fundamentals continue to shape the debate.

CSL Limited develops, manufactures and distributes biopharmaceutical products and vaccines across Australia and major overseas markets including the US, Europe and Asia. Its operations are split across CSL Behring, CSL Seqirus and CSL Vifor, giving the company exposure to plasma-derived therapies, gene therapies, influenza-related products and treatments for iron deficiency and nephrology. That spread matters because CSL is not a single-product story: it is a diversified global healthcare business with recurring demand in several specialised medical categories. The company’s scale is substantial, with a market capitalisation of A$75.6 billion and trailing revenue of A$15.8 billion. Revenue growth of 5.50% indicates the top line is still expanding, but profitability remains under pressure, with a profit margin of -16.33% and trailing earnings per share of -7.52.

Key facts

Price and trend

Valuation

On conventional headline metrics, CSL is difficult to assess in the same way as a profitable mature industrial business because its trailing P/E is shown as 0 and its EPS is negative. That shifts attention to the broader earnings recovery story and to more context-driven measures such as PEG, which is 1.82. The current analyst target price is A$136.61, which is 18.83% below the last price rather than an upside measure. In other words, the market is currently valuing CSL above that target, even though the company’s business quality and global franchise remain significant. The share also does not currently offer a dividend yield, with dividend yield at 0.00% and dividend per share at 0.00, so the investment case is being driven by capital growth and earnings recovery rather than income.

Profitability and growth

Analyst view

Technically, CSL is trading above both its 50-day moving average of A$123.00 and its 200-day moving average of A$143.37, with price-vs-MA readings of 36.83% and 17.39% respectively. That tells you the stock has regained momentum after moving well off its lower base. Even so, it remains below the 52-week high of A$219.64, so the broader recovery is not yet complete. Day-to-day movement also matters: the latest price of A$168.30 was down A$2.90, or 1.69%, from the previous close of A$171.20. CSL’s beta is 0.09, which points to very low measured market volatility relative to the broader market, though that does not remove business risk. For investors, the key issue is whether the company can translate its global franchise and revenue growth into a cleaner earnings profile.

ETFs Featuring CSL

Risks

The main risk is that CSL is still reporting negative profitability, with a -16.33% margin and negative EPS, so the market is relying on future improvement rather than current earnings strength. That makes execution important across all three segments, particularly in a business that depends on specialised products, regulatory oversight and complex global supply chains. The stock has also outpaced the analyst target price, which can leave less room for disappointment if sentiment cools. While the share price sits above its medium- and long-term moving averages, it has already shown that it can be volatile over longer cycles, as reflected in the wide 52-week range from A$90.00 to A$219.64. The absence of a dividend also means shareholders are not being paid to wait for a recovery in earnings.

FAQ